Articles related to ADJUNCTIVE THERAPY

Researchers reported changes in brain functional connectivity after adding N-acetylcysteine to ongoing multiple sclerosis treatment, an early imaging signal that requires confirmation in larger studies with defined dosing and clinical outcomes.

Five years after participation in randomized trials, children with fetal alcohol spectrum disorder who received choline supplementation during early childhood demonstrated higher nonverbal IQ and working-memory performance than peers who received placebo, suggesting the intervention may influence long-term neurodevelopmental trajectories.

The FDA authorized Avulux lenses as a nonpharmacologic adjunct for migraine-associated light sensitivity in patients aged 12 years and older, supported by clinical data showing reduced photophobia and exploratory signals of headache pain improvement in some users.

Adjunctive active VNS was associated with greater suicidal ideation improvement than sham stimulation in patients with markedly treatment-resistant depression. The exploratory analysis was not powered as a confirmatory suicide-outcomes trial.

A network meta-analysis found that long-term vitamin D supplementation added to standard multiple sclerosis therapy was associated with reduced relapse risk and improved disability outcomes.

Creatine supplementation showed mixed effects on depressive symptoms across five randomized trials involving patients with mood disorders. The early findings suggest potential adjunctive benefit in some populations but do not establish a consistent treatment effect.